Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Arcus Biosciences
1 program
1
zanzalintinibPhase 1Small Molecule1 trial
Active Trials
NCT06191796Terminated25Est. May 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
Arcus Bioscienceszanzalintinib

Clinical Trials (1)

Total enrollment: 25 patients across 1 trials

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Start: Jan 2024Est. completion: May 202525 patients
Phase 1Terminated

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space